Magazine
ENEWS
SUBSCRIBE
WEBINARS
PODCASTS
EBOOKS
Edit submissions
Press releases
Media kit
Innovation Awards
Quality & Risk
QRM Process
Pharmaceutical Manufacturing: Is It the Antithesis of Creative Destruction?
July 16, 2008
PAT and QbD can only move forward if the industry sheds its habit of QbA (i.e., quality by analysis)
Girish Malhotra
About the Author
Girish Malhotra | PE
Drug Approvals
FDA approves Italfarmaco Duchenne drug
March 22, 2024
Drug Approvals
Medicare to cover Wegovy for heart disease patients
March 22, 2024
Editors' (re)View
Editors' (re)View: J&J cast-off anti-hypertensive wins approval; Orchard prices MLD therapy at $4.25M
March 22, 2024
Aseptic Processing
Novo Nordisk invests $580M in China site expansion
March 21, 2024
Latest from QRM Process
Optimizing supplier quality management
Engineering Angles: Optimizing the facility design phase
Maintaining compliance beyond the pandemic
Quality woes thrust Emergent back in the spotlight
Redefining quality with analytical monitoring
Compressed air quality
Load More Content